17 results
10-K
2023 FY
MIRA
Mira Pharmaceuticals Inc
1 Apr 24
Annual report
7:00am
in the antidepressant effects of ketamine.
Anti-inflammatory Effects: Depression is increasingly linked with chronic inflammation. Ketamine has been shown to have … , encompassing both acute and chronic toxicology assessments in relevant animal models, including 7 and 28-day studies in rats and dogs. Additionally
8-K
EX-99.2
MIRA
Mira Pharmaceuticals Inc
7 Aug 23
MIRA Pharmaceuticals, Inc. Announces Pricing of $8.9 Million Initial
5:14pm
by the Company, the Company believes that MIRA1a may enhance the therapeutic potential for treating anxiety, cognitive decline, and chronic pain without
8-K
EX-99.1
MIRA
Mira Pharmaceuticals Inc
7 Aug 23
MIRA Pharmaceuticals, Inc. Announces Pricing of $8.9 Million Initial
5:14pm
that MIRA1a may enhance the therapeutic potential for treating anxiety, cognitive decline, and chronic pain without the side effects of plant-based THC
424B4
MIRA
Mira Pharmaceuticals Inc
4 Aug 23
Prospectus supplement with pricing info
1:01pm
decline typically associated with early-stage dementia. Our target patient population is also typically presenting with chronic pain. Our drug … , cognitive decline and chronic pain by potentially striking a balance between the beneficial effects of THC and CBD. MIRA1a achieves this by selectively
424B1
s7ok h0401r
4 Aug 23
Prospectus with pricing info
12:59pm
S-1
qofv4fk
29 Jun 23
IPO registration
4:39pm
S-1
EX-10.5
udtuc5zroj2y x9w
29 Jun 23
IPO registration
4:39pm
DRS/A
EX-10.5
4w7ra
8 Jun 23
Draft registration statement (amended)
12:00am
DRSLTR
e7em0o5kqco5zj0yi8
8 Jun 23
Correspondence regarding draft registration statement
12:00am
DRS/A
pczu2 bdx7mvdx
8 Jun 23
Draft registration statement (amended)
12:00am
UPLOAD
gtmee
30 May 23
Letter from SEC
12:00am
DRS/A
p0huaf22u
2 May 23
Draft registration statement (amended)
12:00am
DRS
i63h4lnr25h
29 Jun 22
Draft registration statement
12:00am
- Prev
- 1
- Next